Can zapping tumors before surgery boost lung cancer treatment?

NCT ID NCT07729670

NEW Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 27, 2026

Summary

This phase 2 trial is testing whether a three-pronged approach—tumor ablation, immunotherapy (tislelizumab), and chemotherapy—can improve outcomes for people with stage II-IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if this combination can eliminate more cancer cells before surgery, potentially leading to better long-term results. The study involves 42 participants and focuses on safety and how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of tumor ablation, the immunotherapy drug tislelizumab, and chemotherapy
What this could lead to: If successful, this approach could offer a more effective way to treat early-stage lung cancer, potentially increasing the chance of complete remission before surgery.
What could go wrong: This is a small, early-phase trial, so results may not apply broadly. Combining multiple treatments also raises the risk of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.